# US 2026/0028345 A1 · Btk degrader and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028345 A1
- Document ID: US20260028345A1
- Status: Published application
- Kind: A1
- Application number: 19/292,469
- Filed: 2025-08-06
- Published: 2026-01-29
- Earliest claimed: 2024-07-26
- Applicants: Ascentage Pharma (Suzhou) Co., Ltd.; Ascentage Pharma Group Corp Limited
- Inventors: Jiantao Hu; Jianyong Chen
- Web page: https://patentgrep.com/patent/US20260028345A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.

## Claims

### Claim 1

A compound selected from
and pharmaceutically acceptable salts and solvates thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is
a pharmaceutically acceptable salt or solvate thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 11 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 19 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 20 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 24 (depends on 1)

The compound of claim 1, wherein the compound is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1)

A method for treating or preventing a disease comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 27 (depends on 26)

The method of claim 26, wherein the disease is mediated by BTK.

### Claim 28 (depends on 26)

The method of claim 26, wherein the disease is cancer.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer is selected from
bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, testicular cancer, urogenital tract cancer, lymphatic system cancer, rectal cancer, larynx cancer, pancreatic cancer, esophageal cancer, and stomach cancer Carcinoma, gallbladder, cervix, thyroid, kidney and skin cancer;
lymphoid hematopoietic tumors, including chronic lymphocytic leukemia acute lymphoblastic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hair cell lymphoma, histiocytic lymphoma, and Burkitt's lymphoma;
hematopoietic tumors of the bone marrow line, including acute and chronic myelogenous leukemia, myelodysplastic syndrome, myelocytic leukemia, and promyelocytic leukemia;
tumors of the central and peripheral nervous systems, including astrocytoma, neuroblastoma, glioma, and schwannoma;
tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma and osteosarcoma; and
other tumors, including melanoma, xenoderma pigmentosum, keratoactanthoma, seminoblastoma, thyroid follicular carcinoma, teratoma, renal cell carcinoma (RCC), pancreatic cancer, myeloma, lymphoblastic leukemia, and glioblastoma.

### Claim 30 (depends on 1)

A method for inhibiting and/or degrading BTK comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the compound of claim 1.
